Stellus Capital Investment Corp. 2019 10-K Summary
Business Context and Reporting Period
Company: Stellus Capital Investment Corp. (Stellus)
Reporting Period: Fiscal year ended December 31, 2019
Structure: Externally managed, closed-end, non-diversified Business Development Company (BDC) regulated under the Investment Company Act of 1940. Stellus has elected to be treated as a Regulated Investment Company (RIC) for federal income tax purposes.
Investment Strategy: Originates and invests primarily in private middle-market companies (typically $5M–$50M EBITDA) via first lien, second lien, and unsecured debt, often with equity co-investments. The portfolio is managed by Stellus Capital Management, LLC.
Key Financial Metrics (Year Ended Dec 31, 2019)
| Metric | 2019 Value |
|---|---|
| Total Investment Income | $58.9 million |
| Net Investment Income | $22.4 million ($1.23 per share) |
| Net Increase in Net Assets from Operations | $26.4 million ($1.45 per share) |
| Net Asset Value (NAV) per Share | $14.14 |
| Total Portfolio Investments (Fair Value) | $628.9 million |
| Portfolio Composition (Fair Value) | 72.4% First Lien, 17.8% Second Lien, 3.5% Unsecured, 6.3% Equity |
| Weighted Average Yield on Debt | 9.2% |
| Asset Coverage Ratio | 229% |
| Cash and Cash Equivalents | $16.1 million |
| Total Liabilities | $377.9 million |
| Outstanding Debt Facilities | Credit Facility: $161.6M; SBA Debentures: $161.0M; 5.75% Notes: $48.9M |
Material Changes vs. Prior Period (2018)
- Portfolio Growth: Total investments at fair value increased from $504.5 million in 2018 to $628.9 million in 2019. The number of portfolio companies grew from 57 to 63.
- Net Investment Income: Decreased slightly from $22.6 million in 2018 to $22.4 million in 2019. This was driven by higher operating expenses (specifically interest expense and incentive fees) offsetting higher investment income from portfolio growth.
- Realized Gains: Net realized gains increased significantly to $19.6 million in 2019 compared to $5.5 million in 2018, primarily due to the realization of equity investments.
- Unrealized Depreciation: The company recorded a net change in unrealized depreciation of $15.5 million in 2019, compared to $1.7 million in 2018, attributed to write-downs on specific investments.
- Yield Compression: The weighted average yield on debt investments decreased from 10.9% in 2018 to 9.2% in 2019.
Guidance, Outlook, and Risks
Management Commentary: Management views the environment for middle-market lending as attractive due to robust demand for debt capital and strong U.S. economic fundamentals. The company continues to focus on direct origination and maintaining a diversified portfolio across various sectors, with Healthcare & Pharmaceuticals being the largest sector at 14.95% of the portfolio.
Risks and Contingencies:
- LIBOR Transition: Significant risk associated with the potential discontinuation of LIBOR after 2021, which could impact the pricing and valuation of floating-rate loans.
- Asset Quality: As of Dec 31, 2019, 11% of the portfolio was rated Category 1 (above expectations), 78% Category 2 (within expectations), and 11% in Categories 3-5 (below expectations or work-out status). Two portfolio companies were on non-accrual status.
- Leverage and Liquidity: The company relies on a $220 million credit facility (with an accordion feature to $250 million) and SBA-guaranteed debentures. Failure to maintain RIC status or asset coverage ratios could restrict distributions and borrowing capacity.
- Conflicts of Interest: Potential conflicts exist regarding co-investments with private funds managed by the investment adviser and the allocation of investment opportunities.
Key Facts for Investor Verification
- Dividend Sustainability: Verify if the $1.36 per share distribution declared in 2019 is fully covered by taxable income, given the $15.5 million unrealized depreciation and the requirement to distribute 90% of taxable income to maintain RIC status.
- Asset Coverage Ratio: Confirm the current asset coverage ratio remains above the 150% regulatory minimum, especially given the high leverage levels ($377.9M liabilities vs. $270.6M net assets).
- LIBOR Exposure: Assess the company's specific transition plan for the 93% of debt portfolio tied to floating rates (LIBOR) and the potential impact on future yields.
- Portfolio Concentration: Review the concentration in the Healthcare sector (14.95%) and the impact of regulatory changes in that sector on portfolio performance.
- Unfunded Commitments: Note the $37.5 million in unfunded commitments to 17 portfolio companies and the company's liquidity position to meet these obligations.